Source: UNIVERSITY OF FLORIDA submitted to NRP
TRANSLATING A DISCOVERY INTO IMPROVING FOOD SAFETY: A NOVEL POULTRY SALMONELLA VACCINE AND DIAGNOSTIC METHODOLOGY TO CONTROL FOODBORNE SALMONELLOSIS
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
ACTIVE
Funding Source
Reporting Frequency
Annual
Accession No.
1023994
Grant No.
2020-67017-33079
Cumulative Award Amt.
$464,360.00
Proposal No.
2020-03308
Multistate No.
(N/A)
Project Start Date
Jan 1, 2021
Project End Date
Dec 31, 2025
Grant Year
2021
Program Code
[A1332]- Food Safety and Defense
Recipient Organization
UNIVERSITY OF FLORIDA
G022 MCCARTY HALL
GAINESVILLE,FL 32611
Performing Department
COMP,DIAG & POP MEDICINE
Non Technical Summary
Nontyphoidal Salmonella is the leading bacterial foodborne pathogen in the U.S., with many outbreaks tracing back to shell eggs, poultry meat, and other poultry products. As a result, implementation of effective strategies for reducing Salmonella contamination of poultry and their products has become a critical public health and economic objective. Despite the regulatory programs and vaccination practices in place for decades against Salmonella, foodborne outbreaks due to Salmonella continue to increase, indicating that more effective vaccines and diagnostic tests are urgently needed. Also, antibiotic-resistant Salmonella are frequently implicated in these outbreaks, necessitating the exploration of novel non-antibiotic interventions to counteract the pathogen in reservoirs, including poultry. In this context, the overall goal of this proposal is to provide new avenues for reducing the incidence of foodborne Salmonella through developing both a novel vaccine effective against multiple Salmonella serovars and a rapid diagnostic tool.The supporting objectives are to: (1) Assess the immunogenicity and efficacy of InvG of Salmonella Enteritidis against a challenge of S. Enteritidis in chickens; (2) Determine if antibodies against InvG can transfer passively from vaccinated hens to progeny chickens, thus providing protection against homologous and heterologous Salmonella; (3) Construct an E. coli-vectored vaccine expressing InvG to minimize colonization of chicken intestines and ovaries by nontyphoidal Salmonella; and (4) Establish a proof of concept, high throughput, rapid test for targeting InvG on the surface of Salmonella found in shell eggs. We expect this research will contribute towards improving U.S. agriculture and ensuring the sustainability of food systems.
Animal Health Component
60%
Research Effort Categories
Basic
10%
Applied
60%
Developmental
30%
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
7123210110060%
7233220104040%
Goals / Objectives
Long-term goal. The long-term goal of this proposal is to reduce foodborne outbreakscaused bynontyphoidal Salmonella associated with poultry meat, eggs, and poultry products by minimizing Salmonella colonization of chickens and contamination of shell eggs by developing an effective vaccine, which can provide protectionagainst multiple Salmonella serovars and a high throughput rapid diagnostic tool for the detection of Salmonella in shell eggs.The specific objectives of the proposal are to:i. Assess the immmunogenicty and efficcay of InvG protein of Salmonella Enteritidis against a challenge of S. Enteritidis in chickens.ii. Determine if antibodies against InvG can transfer passively from vaccinated hens to progeny chickens, thus providing protection against homologous and heterologous Salmonella.iii. Construct an E. coli-vectored vaccine expressing InvG to minimize colonization of chicken intestines and ovaries by nontyphoidal Salmonella.iv. Establish a proof of concept, high throughput, rapid test for targeting InvG on the surface of Salmonella found in shell eggs.
Project Methods
Objective 1. To assess the immunogenicity and efficacy of InvG protein of Salmonella Enteritidis (SE) against a challenge of SE in chickens.Protein purification. InvG of SE will be purified as a 6XHis-tagged protein under denaturing conditions using nickel charged resins.Chicken challenge experiment. Newly hatched chicks will be randomly divided into three groups of 20 chickens. Chickens in group 1 will be vaccinated intramuscularly (IM) with InvG and Quil-A at days 14 and 28 days of age, and challenged with 1010 CFU of SE strain SEE1 in PBS administered orally at 35 days of age. Five birds from each group will be sacrificed on days 2, 7, 14, and 21 post-challenge. Liver, spleen, and cecal contents will be collected at necropsy for Salmonella culture and enumeration. Group 2 (negative control) will receive PBS in place of InvG and SE. Group 3 (positive control) will receive PBS IM on days14 and 28, and SE orally on day 35. Blood will be collected prior to immunization and at the times of euthanasia to measure anti-InvG IgG titers by ELISA. To measure sIgA titers intestinal washing samples will be collected at days 14, 28, and 35.Objective 2. To determine if antibodies against InvG can transfer passively from vaccinated hens to progeny chickens thus providing protection. Here, chickens will be vaccinated with InvG and the eggs laid by the vaccinated hens and their progeny chicks will be monitored for anti-InvG IgG and sIgA antibodies. One-day-old progeny chicks will also be challenged with SE to assess the protection provided by passively transferred antibodies.Chicken homologous Salmonella challenge experiment. Two groups of laying hens will be used. Each group will be housed with 2 male chickens to obtain fertile eggs. After hens in both groups reached a steady state of laying (~26 weeks), hens in one group will be immunized three times with InvG/Quil-A three weeks apart. To ensure that the chickens are Salmonella free, another five birds will be euthanized to collect ceca, ovaries, liver, and spleen for bacterial culture prior to the experiment. Groups treated with PBS (IM)/PBS (oral) and PBS (IM)/Salmonella (oral) will serve as negative and positive controls, respectively. Eggs will be collected daily for 3 months after the last booster vaccination and used for hatching, purifying IgY, or microbiological testing alternatively at 3-day intervals (e.g. day 1 post-immunization for hatching; day 2 post-immunization for purifying IgY; day 3 post- immunization for Salmonella culture).Hens will be bled every week until the end of the experiment to measure anti-InvG IgG titers. Half of the hatched chicks will be euthanized on day 1 to collect organs (liver, spleen and ceca) for Salmonella culture. The other half will be challenged orally with 1010 CFU of SE strain SEE1 as mentioned above. One week after challenge, organs will be collected for Salmonella culture. At the end of the experiment, adult hens will be challenged with 1010 CFU of SE and organs (liver, spleen, ovaries, oviduct, and ceca) will be collected for Salmonella culture, identification, and enumeration.Chicken heterologous Salmonella challenge experiment. Two groups of chickens (30 chickens) will be kept with male birds to obtain fertile eggs. One group will be vaccinated three times with InvG/Quil-A as described under the Objective 2. Eggs laid on days 7/8, 14/15, 21/22, and 28/29 will be hatched to obtain chicks for challenge experiments. Chicks will be divided into four groups at each time point (day 7/8, 14/15, 21/22, or 28/29). Groups 1, 2, and 3 will be challenged with 1010 CFU of S. Typhimurium, S. Heidelberg, or S. Braenderup, respectively. Group 4 will receive PBS and serve as the placebo control.Objective 3. To construct an E. coli-vectored vaccine expressing InvG to minimize colonization of chicken intestines and ovaries by nontyphoidal Salmonella. Due to the limitations in administering a subunit vaccine to chickens under field conditions and inferior protection provided by subunit vaccines, an APEC-vectored vaccine expressing the InvG of SEE1 will be sought. Using E. coli as a vector will also obviate the concerns of using live Salmonella, such as live Salmonella persisting for long periods in chickens or their environment posing a potential threat to human health, reversion to virulence, and interference with Salmonella detection methods.This APEC-vectored vaccine is expected to protect chickens from E. coli-associated peritonitis in addition to reducing Salmonella colonization and shedding. To construct the vectored vaccine expressing Salmonella InvG antigen, the SEE1 antigen will be first cloned into the expression vector pBR322. Then, the cloned vector will be introduced into the PSU-O78-aroA strain.Chicken challenge experimental approach will be similar to the approach described under the Objective 2, except that the chickens will be vaccinated with 1x107 CFU/ml of bacteria in PBS inoculated orally twice (day 14 and 28) in place of four-dose recombinant protein antigen vaccination regimen. Challenging chickens with SE, S. Typhimurium, S. Heidelberg, and S. Branenderup, measurement of anti-InvG antibodies in the chicken sera, intestinal washings, and eggs, and collection of tissues, bacterial culture will be performed as described under the Objective 2.Objective 4. Establish a proof of concept high throughput, rapid test for targeting InvG on the surface of Salmonella found in shell eggs. In year 1, an electrically active filter with interdigitated electrodes will be fabricated by laser carbonization of polyimide with a 405 nm pulsed laser (3, 27, 70). To determine the optimum material for filtration, tracer study experiments will be conducted using both emulsion-coated cellulose paper and nitrocellulose membranes as the backing material for the flexible carbon circuit. After forming the electro-filter milter, a pulsed Nd:Yag laser will be used to perforate the carbon circuit (10 um holes) in various geometries. Various perforation geometries will be tested, and tracer studies will be repeated with fluorescent dyes to optimize the flow rate for testing while simultaneously limiting dead zones on the filter. The dead zones will be visualized with epifluorescent microscopy (FITC filters). Once the perforated hole geometry is optimized for buffer, the experiment will be repeated with egg yolk at various dilutions to determine the optimum fluid viscosity for the flow-through test.In year 2, the optimum methods for metallization of the performations will be investigated, starting with nanoplatinum and nanogold based on our previous work (70). The metal-coated carbon surface will then be functionalized with InvG-T3SS by first tholating the protein using Traut's reagent, and then determining the optimum adsorption for maximum surface coverage. The flow through tests will be repeated in the presence of the InvG-T3SS protein to investigate non-specific binding and clogging. In addition, we will share the protocol with Dr. Carmen Gomes at ISU for a secondary validation analysis with thiolated antibodies used in her current biosensors for targeting extracellular proteins on Salmonella. We will collaborate to determine the optimum protein adsorption for maintaining flow while limiting non-specific binding. As a control we will repeat the testing with thiolated avidin as a capture probe and biotinylated microbeads as the capture target. In year 3, we will challenge the flow through system by first capturing bacteria in buffer, and then gradually increase the viscosity and complexity of the testing medium. We will repeat trials in vegetable broth and finally diluted yolk. Electrochemical impedance spectroscopy will be used for real time analysis of cell capture, and all measurements will be validated with AOAC methods (PCR and cell culture). Protocols for all cell detection studies will be shared with Dr. Gomes for secondary validation using antibodies.

Progress 01/01/23 to 12/31/23

Outputs
Target Audience:This study targets researchers in poultry disease, vaccine development, and biosensor development, as well as veterinarians, diagnosticians, and poultry industry personnel. Additional target audiences are post-doctoral fellows, graduate students, DVM trainees, and undergraduate trainees. Changes/Problems:There was a delay in animal experiments due to animal housing availability. However, we are convinced that we can complete the proposed experiments in time before the project end date. What opportunities for training and professional development has the project provided?The project has trained three graduate students and one Post-doctoral Associate, who continue to work on the project. Four undergraduate students were also trained under the project. Undergraduate student training included learning the best laboratory practices, general microbiology and molecular biology techniques, chicken experiments, and biosensor technology. Training has also included writing and presentation skills. How have the results been disseminated to communities of interest?Results have been disseminated through presentations and manuscripts. What do you plan to do during the next reporting period to accomplish the goals?During the next reporting period: (i) complete the passive immunization experiment mentioned under Objective 2, (ii) assess the immunogenicity and efficacy of the APEC-vectored vaccine against Salmonella Enteritidis challenge, (iii) present research results at the AAAP meeting in June 2024, (iv) submit 3-4 manuscripts, and (v) complete the project and submit the final report.

Impacts
What was accomplished under these goals? During this review period: Objective 1. Assess the immunogenicity and efficacy of InvG protein of Salmonella Enteritidis against a challenge of S. Enteritidis in chickens.Chickens were vaccinated three times intramuscularly with recombinant InvG at 2, 4, and 6 weeks of age and then challenged with Salmonella Enteritidis orally one-week post-vaccination. The vaccinated chickens elicited a robust serum antibody response (IgG/IgY) against InvG as determined by ELISA.However, there was no significant difference in the mucosal antibody response (IgA) in the intestinal mucosa of the vaccinated birds compared to the unvaccinated controls when the vaccine was administered intramuscularly. Further, there was a reduction of Salmonella counts in the ceca and spleen of vaccinated chickens compared to the unvaccinated control group. There was no significant difference in the bacterial counts in the livers of vaccinated and unvaccinated chickens. Objective 2. Determine if antibodies against InvG can transfer passively from vaccinated hens to progeny chickens, thus providing protection against homologous and heterologousSalmonella. This experiment is currently underway. We vaccinated hens in production by administering recombinant InvG intramuscularly three times two weeks apart, starting from 21 weeks of age. Vaccinated hens produced robust serum IgG response as determined by ELISA. We will continue to monitor serum IgG response and IgY (IgG) response in the egg yolk for four months. Eggs will be collected for hatching, and hatched chickens as well as vaccinated hens, will be challenged with Salmonella Enteritidis, Salmonella, Typhimurium, Salmonella Kenturcky. Objective 3. Construct an E. coli-vectored vaccine expressing InvG to minimize colonization of chicken intestines and ovaries by nontyphoidal Salmonella. The initial construct did not express the InvG protein in vivo as expected. We changed the vector construct and are currently verifying its ability to express InvG. Chicken experiments are planned for July 2024. Objective 4. Establish a proof of concept, high throughput, rapid test for targeting InvG on the surface of Salmonella found in shell eggs. Both Clemson University and Iowa State University have been working on detecting infectious pathogens using electrochemical impedance methods based on laser-inducedgraphene and stimuli-responsive brush platforms in complex sample matrices.In addition to Salmonella, they targeted Listeria monocytogenes, Escherichia coli, norovirus, and SARS-CoV-2. Although recombinant InvG could be used as capture material to detect Salmonella, the efficiency was not as efficient as the use of DNA aptermers as the capture material. While improving the efficiency of InvG protein-based assay, we are currently working on the use of monoclonal antibodies as capture material as an alternative approach. We immunized Balb/c mice with small synthetic peptides of InvG purchased from GenScript and are in the process of hybridoma generation and screening.

Publications

  • Type: Book Chapters Status: Published Year Published: 2023 Citation: Hjort, R. G., Pola, C. C., Soares, R. R. A., Oliveira, D. A., Stromberg, L., Claussen, J. C., Gomes, C. L. 2023. Advances in biosensors for detection of foodborne microorganisms, toxins and chemical contaminants. In: Encyclopedia of Food Safety, 2nd Edition. Elsevier. https://doi.org/10.1016/B978-0-12-822521-9.00187-8.
  • Type: Conference Papers and Presentations Status: Published Year Published: 2023 Citation: McLamore, E.S. (2023) Pathogen detection in agricultural systems using portable biosensors. Introduction to Biosystems Engineering course, Clemson University, Guest Lecture, October 10. Oliveira, D. A., Pola, C. C., Soares, R. R. A., Hjort, R., Claussen, J. C., McLamore, E. S., Gomes, C. L. 2023. Rapid and label-free bacterial pathogen detection based on graphene and stimuli-responsive nanobrushes for in-field water quality monitoring. American Chemical Society, ACS National Meeting and Expo Fall 2023, San Francisco, CA, August. Neelawala, R., Edison, L. K., Gottapu, C., Kariyawasam, S. 2023. An avian pathogenic E. coli vector system for delivering heterologous vaccine antigens in poultry. Annual Meeting of the American Association of Avian Pathologists (AAAP). Jacksonville, FL, June 11-14. Neelawala R, Edison LK, Gottapu C, Kariyawasam S. 2023. An avian pathogenic E. coli vector system for delivering heterologous vaccine antigens in poultry. University of Florida College of Veterinary Medicine Research and Phi Zeta Celebration. Gainesville, FL, April 13-14. Hjort, R., Soares, R. R.A., Miliao, G. L., Pola, C. C., Almeida, C. J., Claussen, J. C., Gomes, C. L. 2023. Future of biological sensing for food, agricultural, and environmental applications: opportunities and challenges. Institute of Biological Engineering annual meeting. Ames, IA, April. Pola, C. C., Rangnekar, S. V., Szydlowska, B. M., Sheets, R. L., Hersam, M. C., Claussen, J. C., Gomes, C. L. 2023. Electrochemical detection of viruses using printed graphene-based immunosensors. Institute of Biological Engineering annual meeting. Ames, IA, April. Oliveira, D. A., Soares, R. S., Pola, C. C., Hjort, R. G., Claussen, J. C., Gomes, C. L. 2023. Electrochemical sensors based on laser induced graphene for food safety monitoring Pittcon Conference & Expo 2023, Philadelphia, PA, March.
  • Type: Conference Papers and Presentations Status: Accepted Year Published: 2024 Citation: Neelawala, R., Gorrapu, C., Roberts, J.F., Edison, L., Butcher, G. D. 2024. Preliminary evaluation of InvG as a novel Salmonella vaccine candidate: Immunogenicity and efficacy in layer chickens. Annual meeting of the American Association of Avian Pathologists (AAAP). St. Louis, MO, July 9-11. Neelawala, R., Gorrapu, C., Roberts, J.F., Edison, L., Butcher, G. D. 2024. Assessment of a novel poultry Salmonella vaccine candidate: efficacy, immunogenicity, and future perspectives. University of Florida College of Veterinary Medicine Research and Phi Zeta Celebration. Gainesville, FL, April 18. Casso-Hartmann, L., Moreira, G., Tzeng, T-R., Vanegas D., McLamore, E. S. 2024 Electrochemical Detection of Salmonella enterica using a laser inscribed graphene biosensor. ACS Spring Meeting, New Orleans LA. Electrochemical Sensors for Healthcare and the Environment. 1st place prize, Graduate student category. March 19. Casso-Hartmann, L., Moreira, G., Tzeng, T-R., Vanegas D., McLamore, E. S. 2024 Electrochemical Detection of Salmonella enterica using a laser inscribed graphene biosensor. Global Alliance for Rapid Diagnostics (GARD) Annual Symposium, March 15.


Progress 01/01/22 to 12/31/22

Outputs
Target Audience:Audiences have included researchers and educators in avian medicine, veterinary medicine, molecular biology and vaccinology, biological engineering, veterinarians, veterinary students, graduate and undergraduate students. Changes/Problems:One of our chicken experiments was faced with a contamination issue. We believe the contamination occurred in the egg incubation room because in ovo Salmonella experiments were done in the same room but in different incubators. The chicken housing facility, including the isolators and the incubators, was decontaminated. New experiments are currently in progress. What opportunities for training and professional development has the project provided?This project has trained one PhD student, one Master's student, and one under-represented (female, African American) research scientist who are continuing to work on the project. A new Post-doctoral Fellow recruited last year has also been working on the project. A couple of undergraduate and DVM trainees were also trained. Training has consisted of learning best laboratory practices, general microbiology and molecular biology techniques, and conducting chicken experiments. Training has also included writing and presentation skills. How have the results been disseminated to communities of interest?Results have been disseminated through presentations and manuscripts. What do you plan to do during the next reporting period to accomplish the goals?During the next reporting period, we plan to: (i) complete vaccine efficacy studies stated under Objective 1, (ii) start the passive immunization experiment mentioned under Objective 2, (iii) assess the immunogenicity and efficacy of the APEC-vectored vaccine against S.Enteritidis challenge, and (iv) present research results at the AAAP meeting in June 2023.

Impacts
What was accomplished under these goals? Objective 1. Assess the immunogenicity and efficacy of InvG protein of Salmonella Enteritidis against a challenge of S. Enteritidis in chickens. We completed immunogenicity studies by vaccinating the chickens with recombinant InvG twice two weeks apart via intramuscular route. Chickens showed high serum antibody titers as determined by an ELISA developed under this project during Year 1. We challenged the vaccinated birds with S.Enteritidis to determine the vaccine efficacy, but the negative control group (unvaccinated, unchallenged) was contaminated invalidating the entire experiment. We are in the process of repeating the experiment. Objective 3. Construct an E. coli-vectored vaccine expressing InvG to minimize colonization of chicken intestines and ovaries by nontyphoidal Salmonella. We have completed constructing the avian pathogenic E. coli (APEC)-vectored vaccine expressing InvG. First, we created an APEC double mutant strain by deleting aroA and asd genes.This mutant construct was tested for safety in 1-day old-chickens by administering the vaccine strain via the intramuscular route. Then, we transformed the double mutant strain with the Asd-expressing plasmid pYA4515 carrying the invG gene to create the vaccine strain. We demonstrated the InvG is expressed on APEC cell surface in vitro by subcellular fractionation.More experiments are currently underway to characterize the expressed protein and to confirm plasmid stability in the APEC vector strain. Objective 4. Establish a proof of concept, high throughput, rapid test for targeting InvG on the surface of Salmonella found in shell eggs. We were able to preserveInvG in its native form by adding X1 critical micelle concentration of SDS into the protein preparation. Adding SDS at this concentration did not affect the downstream biosensor workflow. During this reporting period,we have made major progress in the development of our flow through system as summarized below in the following four tasks: 4.1 Screening of binding kinetics using biolayer interferometry. We have developed a framework for using high throughput protein-ligand interaction kinetics in the design of EIS biosensors using different concentrations of InvG in the presence of S. Enteritidis. These interaction studies help to optimize surface coverage optimization (maximize binding kinetics and thus minimize steric hindrance). Ongoing work is repeating these studies with different matrix challenges (e.g., exogenous LPS, non-target cells). 4.2. Establishment of graphene electrode platform for high throughput analysis. In this task, a quality control (QC) study was conducted for improving the translation of our work. Along these lines, we have recently developed numerous open source protocols to improve repeatability by other research groups. We developed a simple technique based on repetitive sweeps of CV to condition LIG working electrodes (this technique is common to electrochemistry or sensor labs and is widely available). Analysis of CV data for each sweep (peak redox and charge/discharge dynamics) were used to characterize electrode performance. In addition, an LIG biochip (working, counter and reference electrode in one sensor platform) was also designed and tested. A protocol is under development for sharing this technique using the open source Protocol I/O. 4.3. Laser patterning of cavities for high sample throughput. During our preliminary analysis, we have tested various cavity densities to determine the affect(s) of carbon electrode perforation on electrochemical signal transduction. These preliminary data indicate our ability to control the perforated cavity location as well as diameter. We used a CO2 laser to pattern various microchannel arrays in LIG electrodes, starting from single channel electrodes to orthogonal arrays. We have characterized the electrochemical behavior of micro-cavities. By measuring the change in current during sample filtration, we are currently creating a library of digital fingerprints for various samples. Based on the area under the curve analysis of time series, the test will be used to determine one of two control systems as a binary alarm for false positives/negatives: i) if the sample viscosity is within the range of 10% egg yolk (sample control), or ii) if the capture system was over saturated with bacteria-sized particles (confirmation of contamination). 4.4. Loading of biorecognition element. Our proof of concept work to date has focused on adsorption of an aptamer that is highly selective for InvG (control study). In the next report we will show the biofunctionalization of LIG electrodes with InvG and compare the DNA aptamer coating. Before loading aptamer, the decapped solution was heated to 90° C for 5 minutes (to unfold DNA), and then cooled to room temperature for 10 minutes (to refold). For loading experiment, an aliquot of 10 µl decapped, refolded aptamer solution was drop cast on the surface of nPt-LIG working area, incubated in the BSL2 hood for 10 minutes, gently rinsed with 500 µl bicarbonate buffer, and then connected to the potentiostat for EIS analysis. This process was repeated for five subsequent loading steps.

Publications

  • Type: Conference Papers and Presentations Status: Published Year Published: 2022 Citation: Yifan Tang, Diana Vanegas and Eric McLamore. Quality Control for LIG Electrodes. Annual IBE conference. Athens, GA. April 7, 2022.
  • Type: Conference Papers and Presentations Status: Accepted Year Published: 2023 Citation: Roshen N. Neelawala, Lekshmi Edison, Chaitanya Gottapu, and Subhashinie Kariyawasam. An Avian Pathogenic E. coli Vector System for Delivering Heterologous Vaccine Antigens in Poultry. UF-CVM Phi Zeta Research Celebration. Gainesville, Florida. April 2023.
  • Type: Conference Papers and Presentations Status: Accepted Year Published: 2023 Citation: Roshen N. Neelawala, Lekshmi Edison, Chaitanya Gottapu, and Subhashinie Kariyawasam. An Avian Pathogenic E. coli Vector System for Delivering Heterologous Vaccine Antigens in Poultry. Annual Meeting of American Assocation of Avian Pathologists. Jacksonville, Florida. June 2023.
  • Type: Journal Articles Status: Submitted Year Published: 2023 Citation: One manuscript under review describing the electrode system (Tang et al., submitted to RSC Analyst)


Progress 01/01/21 to 12/31/21

Outputs
Target Audience:Under this project, experiential learning opportunities were provided to one undergraduate student and one veterinary student. Both students represented racial and ethnic minority groups. In addition, one graduate student and one post-doctoral fellow were trained on the laboartory and animal experiment techniques required for the project, as needed. Changes/Problems:We do not anticipate any changes to the project. Yet, the activities were largely hampered by the COVID-19 pandemic and separation of the post-doc (Dr. Ananta Arukha) from the university. Now that we have hired a new post-doc (Dr. Lekshmi Edison) and the graduate student has been trained on laboratory techniques and chicken experiment techniques required for the project, we anticipate a significant progress in 2022. What opportunities for training and professional development has the project provided?One-on-one training was provided to one undergraduate, one veterinary student, one graduate student, and one post-doctoral student.The project was largely hampered by the COVID-19 pandemic, but the undergraduate student presented her research at the Florida Veterinary Scholars' Annual Meeting. Additionally, the post-doc was given the opportunity to train undergraduate, graduate, and veterinary students to improve his student training and mentoring skills.? How have the results been disseminated to communities of interest? Nothing Reported What do you plan to do during the next reporting period to accomplish the goals? Objective 1. Assess the immmunogenicity and efficacy of InvG protein ofSalmonellaEnteritidis against a challenge ofS. Enteritidis in chickens. Now that the ELISA is ready, wewill begin chicken experiments toassess the immunogenicity and efficacy in May, 2022 and complete the work before the end of the year. Objective 2. Determine if antibodies against InvG can transfer passively from vaccinated hens to progeny chickens, thus providing protection against homologous and heterologousSalmonella. We anticipate to initiate chicken experiments toassess passive protection conferred by InvG in November 2022. But this will largely depend on availability of chicken. Objective 3. Construct anE. coli-vectored vaccine expressing InvG to minimize colonization of chicken intestines and ovaries by nontyphoidalSalmonella. We will complete construction of the E. coli vectored vaccine, which is currently in progress, by December 2022. Objective 4.Establish a proof of concept, high throughput, rapid test for targeting InvG on the surface ofSalmonellafound in shell egg. InvG protein in its native from will be provided to Dr. McLamore's group in Clemson University to develop the biosensordiagnostic platform in April 2022.

Impacts
What was accomplished under these goals? Under Objectives 1 and 2: 1. Antibodies (hyperimmune sera) were raised against InvG protein in specific pathogen-free chickens. 2. An Enzyme-linked Immunosorbent Assay (ELISA) was developed to measure antibody responses against InvG protein in vaccinated chickens. Under Objective 3. 1. We obtained the Asd+ recombinant expression plasmid, pYA4515, from Dr. Roy Curtiss and began the experiments to construct the InvG-expressing avian pathogenic Escherichia coli aroA mutant-vectored vaccine strain.

Publications